Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0151814 (coronary occlusion)
 3,687 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

CLS 2210 (calcium dobesilate) has been shown to reduce the volume of myocardium infarcted after coronary artery occlusion in the dog. This study, in rats, was designed to determine whether CLS 2210 would reduce mortality and infarct size after coronary occlusion. Another goal was to ascertain whether a duration of administration exceeding 6 h improves survival. Experiments were performed in rats with myocardial infarction induced by coronary artery ligation. In one series, rats were blindly randomized into four groups receiving, over a period of 6 h, either 200, 400 or 800 mg/kg of CLS 2210 or a placebo. In a second series, the animals were randomized to receive as initial dose a bolus of either 50 mg/kg of CLS 2210 by intravenous infusion or placebo followed by 25 mg/kg/h of the same drug or placebo over 24 h: mortality and infarct size were assessed after 24 h. A third series of rats received the same dosage schedule of CLS 2210 or placebo, but mortality was evaluated after 1 week, to ascertain whether CLS 2210 merely postponed death. Our first goal in this study was to ascertain whether CLS 2210 would improve survival after coronary artery occlusion in the rat. In the placebo group, death occurred in 61 of 112 rats (54.5%). In the CLS-2210-treated group, mortality was sharply reduced, to 68 of 182 (37.3%; p less than 0.01). Mortality in rats receiving CLS 2210 for 6 h was significantly lower, 35.6%, when compared to the placebo which was 51.9% (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Effect of CLS 2210 (calcium dobesilate) on survival and myocardial infarction size in the rat: influence of dose and duration of treatment. 155 13

The effects on the evolution of canine myocardial infarction (MI) of the lymphagogues hyaluronidase (hyaluronate glucanohydrolase) (known to reduce the size of MIs) and calcium dobesilate (calcium, 2,5-dihydroxybenzenesulfonate, CLS 2210) were compared in a coded, placebo-controlled study in 48 dogs, during the first 24 h after coronary occlusion. MI was induced by embolization of the anterior descending branch of the left coronary artery. The animals were given either a placebo, CLS 2210, or hyaluronidase by intravenous infusion begun immediately after embolization and continued for 24h. The volume of myocardial tissue at risk was evaluated at 2 and 24 h by ungated computed tomography (CT), and after necropsy by staining myocardial sections with triphenyl tetrazolium chloride (TTC). Electrocardiography and estimation of serum creatine kinase (CK) activity were also performed. In the 25 animals that survived 24 h, the results of all tests showed that there was less myocardial damage in the animals treated with the two lymphagogues than in those treated with placebo, and less damage with CLS 2210 than with hyaluronidase. The good correlation between the volume of ischemic tissue as assessed by CT in vivo and as assessed by TTC staining after necropsy (r = 0.959) confirms that the CT perfusion phase defect accurately reflects the volume of tissue at risk during the evolution of MI. This study has shown that CLS 2210 is at least as effective as hyaluronidase in reducing myocardial damage due to coronary artery occlusion in dogs.
 ...
PMID:Myocardial infarction treated with two lymphagogues, calcium dobesilate (CLS 2210) and hyaluronidase: a coded, placebo-controlled animal study. 169 85

To examine the role of cardiac lymphatic drainage in myocardial infarction, we quantified the effect of a lymphogogue, CLS 2210, on the number and appearance of myocardial lymphatics as well as the electrocardiogram following coronary occlusion in the dog. Thirty minutes and six hours after intravenous administration of the benzenesulfonate compound, (CLS 2210) cardiac lymphatics in the distribution of the left anterior descending coronary artery (LAD) were determined and further delineated by postmortem cardiac lymphangiograms. The results were compared with treated and untreated dogs without and with descending coronary artery ligation including the noninfarcted zone; that is, myocardium within the distribution of left circumflex coronary (LCC) artery. After 30 minutes in dogs receiving CLS 2210 without LAD ligation, number of lymphatics (point count/cm2, see Methods) were respectively--LAD zone: 2.62 +/- 0.11 or 10.9% of left ventricular (LV) surface; LCC zone: 2.87 +/- 0.10, whereas after six hours--LAD zone 8.04 +/- 0.03 or 32.3% LV surface; LCC zone--8.13 +/- 0.06 compared with untreated controls--LAD zone 1.71 +/- 0.11 or 6.6% of LV surface; LCC zone 1.65 +/- 0.12 (p less than 0.0001). At similar intervals in dogs with LAD ligation, the findings were at 30 minutes LAD zone 0.78 +/- 0.07 or 3.1% of LV surface and at 360 minutes was 0.80 +/- 0.08 or 3.3% of LV surface. In conjunction with CLS 2210 administration, however, LAD zone showed at 30 minutes 2.50 +/- 0.12 or 10% of LV surface (p less than .01) and at 360 minutes was 10.34 +/- 0.03 or 35.1% of LV surface.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Influence of a lymphagogue, CLS 2210, on regional cardiac lymphatics and the electrocardiogram after coronary artery occlusion in the dog. 375 3

Earlier studies have shown that hyaluronidase exerts a potent influence upon the lymphatic system of the myocardium and that it reduces the size of myocardial infarcts after coronary occlusion. In this study we compared, in mongrel dogs, the effect of intravenous hyaluronidase or CLS 2210 upon the cardiac lymphatic vessels. We observed that in CLS 2210-treated animals the number of visualized cardiac lymphatic vessels was significantly higher than in the hyaluronidase-treated control group. We have previously demonstrated a cardioprotective effect of hyaluronidase in the treatment of acute myocardial infarction. The present experimental data indicate that intravenous CLS 2210 may have a definite role in the management of acute coronary occlusion. Further studies are needed to confirm these preliminary findings.
 ...
PMID:CLS 2210, hyaluronidase and the cardiac lymphatic system. 383 39